UNICA IRIS Institutional Research Information System

MARONGIU, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 151.744
NA - Nord America 12.220
AS - Asia 5.286
SA - Sud America 927
AF - Africa 207
OC - Oceania 64
Continente sconosciuto - Info sul continente non disponibili 4
Totale 170.452
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 144.764
US - Stati Uniti d'America 11.973
NL - Olanda 3.816
SG - Singapore 2.006
CN - Cina 1.617
BR - Brasile 689
UA - Ucraina 677
SE - Svezia 672
VN - Vietnam 504
DE - Germania 417
GB - Regno Unito 346
FI - Finlandia 341
FR - Francia 256
HK - Hong Kong 221
IN - India 146
BD - Bangladesh 140
CA - Canada 139
KR - Corea 91
AR - Argentina 75
IQ - Iraq 70
MX - Messico 67
ZA - Sudafrica 63
RU - Federazione Russa 57
TR - Turchia 56
AU - Australia 53
JP - Giappone 53
ES - Italia 52
PK - Pakistan 50
AT - Austria 46
ID - Indonesia 44
CO - Colombia 40
IE - Irlanda 40
IR - Iran 37
EC - Ecuador 36
PL - Polonia 36
EG - Egitto 32
BE - Belgio 30
MA - Marocco 29
PH - Filippine 28
MY - Malesia 27
SA - Arabia Saudita 26
RO - Romania 25
UZ - Uzbekistan 22
CL - Cile 21
CH - Svizzera 20
VE - Venezuela 20
TN - Tunisia 19
KE - Kenya 18
TW - Taiwan 18
HU - Ungheria 17
JO - Giordania 17
LT - Lituania 17
PE - Perù 17
ET - Etiopia 15
CZ - Repubblica Ceca 14
PY - Paraguay 14
AE - Emirati Arabi Uniti 13
AL - Albania 13
TH - Thailandia 13
DK - Danimarca 12
BG - Bulgaria 11
IL - Israele 11
NZ - Nuova Zelanda 11
RS - Serbia 11
KZ - Kazakistan 10
NP - Nepal 10
BA - Bosnia-Erzegovina 9
AZ - Azerbaigian 8
DZ - Algeria 8
JM - Giamaica 8
SD - Sudan 8
GR - Grecia 7
UY - Uruguay 7
BH - Bahrain 6
LB - Libano 6
PR - Porto Rico 6
PT - Portogallo 6
CR - Costa Rica 5
CY - Cipro 5
GE - Georgia 5
NO - Norvegia 5
BY - Bielorussia 4
EE - Estonia 4
MK - Macedonia 4
MT - Malta 4
BO - Bolivia 3
CI - Costa d'Avorio 3
GT - Guatemala 3
GY - Guiana 3
HR - Croazia 3
KW - Kuwait 3
LU - Lussemburgo 3
MU - Mauritius 3
NG - Nigeria 3
NI - Nicaragua 3
OM - Oman 3
PA - Panama 3
QA - Qatar 3
SK - Slovacchia (Repubblica Slovacca) 3
SY - Repubblica araba siriana 3
Totale 170.411
Salva come PNG Salva come JPEG
Città #
Cagliari 140.500
Amsterdam 3.746
Uta 3.426
Fairfield 1.365
Ashburn 969
Singapore 919
Woodbridge 838
Houston 656
Chandler 644
Dallas 638
San Jose 593
Seattle 556
Wilmington 528
Boardman 516
Ann Arbor 463
Cambridge 452
Nyköping 442
Jacksonville 350
Beijing 305
Los Angeles 214
Helsinki 207
Hong Kong 195
Council Bluffs 184
The Dalles 175
Dearborn 158
Ho Chi Minh City 153
Lauterbourg 146
New York 139
Santa Clara 129
Boston 125
Shanghai 117
Nanjing 112
Hanoi 99
Buffalo 91
Hefei 88
San Diego 85
Milan 76
Seoul 73
São Paulo 62
Rome 57
Toronto 57
Dong Ket 56
Guangzhou 56
Hebei 55
Munich 52
Shenyang 49
London 47
Redwood City 46
Frankfurt am Main 45
Redondo Beach 41
Changsha 37
Chicago 36
Nanchang 36
Orem 36
Tianjin 36
Jiaxing 34
Nuremberg 32
Atlanta 30
Verona 30
Vienna 30
Baghdad 29
Dublin 28
Brussels 27
Rio de Janeiro 27
Brooklyn 26
Johannesburg 26
Mexico City 25
Warsaw 25
Phoenix 24
Tokyo 24
Orange 23
Brandenburg 22
Denver 22
Millbury 22
Da Nang 21
Lahore 21
Chennai 20
Jinan 20
Norwalk 20
Sassari 20
Stockholm 20
Tashkent 20
Haiphong 19
Manchester 19
Montreal 17
Mountain View 17
Sydney 17
Turku 17
Bogotá 16
Cape Town 16
Nairobi 16
Redmond 16
San Francisco 16
Zhengzhou 16
Ankara 15
Dhaka 15
Ningbo 15
Belo Horizonte 14
Paris 14
Guayaquil 13
Totale 162.232
Salva come PNG Salva come JPEG
Nome #
Vaping effects on asthma: results from a web survey and clinical investigation 2.981
Sampling variability in hepatic iron concentration in beta-thalassemia 2.873
Heterogeneity of Antiphospholipid Syndrome (APS) as Characterized by Brain Perfusion Techniques. Towards New Ways of Syndrome Characterization 2.812
The venous thromboembolic risk and the clot wave analysis: a useful relationship? 2.772
Prophylaxis of peripartum haemorrhage using recombinant factor VIIa (rfVIIa) in pregnant women with congenital factor VII deficiency: A case report and literature review 2.756
Acquired factor VIII inhibitor and subsequent development of non-Hodgkin's lymphoma: a case report and review of the literature 2.583
Dabigatran overdose: a case report of acute hepatitis. Extracorporeal treatment. 2.572
Olanzapine-associated portal and superior mesenteric vein thrombosis 2.520
Are prothrombin time and clot waveform analysis useful in detecting a bleeding risk in liver cirrhosis? 2.436
alpha 2 Antiplasmin and disseminated intravascular coagulation in liver cirrhosis 2.397
Telemedicine can improve the quality of oral anticoagulation using portable devices and self-testing at home 2.313
Clot wave analysis and thromboembolic score in liver cirrhosis: two opposing phenomena 2.302
A retrospective cohort study of patients with pulmonary embolism: The impact of comorbidities on patient's outcome 2.188
Empathy and the Educational Approach to Patients With Atrial Fibrillation Treated With Direct Oral Anticoagulants 2.184
Underuse of anticoagulant therapy in hospitalized older patients: comment on the article of Wojszel et al 2.169
Management of Patients Taking Oral Anticoagulants Who Need Urgent Surgery for Hip Fracture 2.155
Pulmonary Thrombosis: A Clinical Pathological Entity Distinct from Pulmonary Embolism? 2.078
Human Leukocyte Antigen Complex and Other Immunogenetic and Clinical Factors Influence Susceptibility or Protection to SARS-CoV-2 Infection and Severity of the Disease Course. The Sardinian Experience 2.025
Clot Waveform Analysis: From Hypercoagulability to Hypocoagulability - A Review 2.019
A Sardinian Family with Factor XI Deficiency 1.998
Ultrastructural findings of lung injury due to Vaccine-induced Immune Thrombotic Thrombocytopenia (VITT) following COVID-19 vaccination: a scanning electron microscopic study 1.967
Vaccine-induced severe thrombotic thrombocytopenia following COVID-19 vaccination: A report of an autoptic case and review of the literature 1.901
A “Catastrophic” Heparin-Induced Thrombocytopenia 1.890
The hemostatic system. 1st Part 1.814
Points of Care Testing International Normalized Ratio: Are They Useful for Monitoring Vitamin K Antagonists in a Thrombosis Center? 1.810
Fibrinogen and D-dimer levels in autoimmune subclinical and overt hypothyroidism and effects of levothyroxine treatment. 1.780
Molecular pathways triggered by COVID-19 in different organs: ACE2 receptor-expressing cells under attack? A review 1.753
Epidemiology of infection with HIV-1 in Sardinia: a multicentre prospective study 1.711
Point-of-care testing INR: an overview 1.683
Has time come for the use of direct oral anticoagulants in the extended prophylaxis of venous thromboembolism in acutely ill medical patients? No 1.663
Pulmonary thrombosis in 2019-nCoV pneumonia? 1.658
Uneven hepatic iron and phosphorus distribution in b-thalassemia 1.657
Risk of reoperation in bioprosthetic valve patients with indication for longterm anticoagulation. Results from the observational retrospective multicentre PLECTRUM study 1.650
Optimizing tailored DIEP flap insetting in unilateral immediate free autologous breast reconstruction 1.647
Mechanical prosthetic heart valves: Quality of anticoagulation and thromboembolic risk. The observational multicenter PLECTRUM study 1.577
Immunological aspects in anti-HIV seronegative drug addicts. Correlation with the duration of heroin addiction and other viral infections 1.572
Direct oral anticoagulants: what can we learn? 1.569
Comparison of prothrombin time INR and clot waveform analysis performed with 129-mmol/L and 105-mmol/L citrate tubes 1.564
Fatal Cytopenia Induced by Low-Dose Methotrexate in Elderly With Rheumatoid Arthritis. Identification of Risk Factors 1.515
T lymphocyte subsets and viral infections in Sardinian parenteral drug abusers: relationship to HIV infection 1.489
The criteria of the Italian Federation of Thrombosis Centres on DOACs: a ‘‘real world’’ application in nonvalvular atrial fibrillation patients already on Vitamin K Antagonist 1.485
Allele 4G of gene PAI-I associated with prothrombin mutation G20210A increases the risk for venous thrombosis 1.459
Thrombosis centres and AVKs monitoring in COVID-19 pandemic 1.446
Ultrasound-guided fine-needle aspiration biopsy of thyroid nodules in patients on oral anticoagulants 1.393
[Immunological aspects in anti-HIV seronegative drug addicts. Correlation with the duration of heroin addiction and other viral infections]. FT Aspetti immunologici nei tossicodipendenti anti-HIV sieronegativi. Correlazione con la durata di assunzione dell'eroina e con altre infezioni virali. 1.373
Fondaparinux: Should It Be Studied in Patients with COVID-19 Disease? 1.368
Direct inhibitors of thrombin and factor Xa: the importance of laboratory skills 1.352
A guide to oral anticoagulation 1.333
Hyperhomocysteinemia: could the post-methionine oral loading test sometimes be avoided? 1.291
Warfarin prescription in patients with nonvalvular atrial fibrillation and one non-gender-related risk factor (CHA(2)DS(2)VASc 1 or 2): a treatment dilemma 1.289
The Italian START-Register on anticoagulation with focus on atrial fibrillation 1.268
Antiphospholipid syndrome patients: The performance of Coagucheck XS in the monitoring of Vitamin K-Antagonists 1.255
Heparins and 2019-nCoV infection: a narrative review 1.247
A ‘‘two-step’’ educational approach for patients taking oral anticoagulants does not improve therapy control 1.232
Thyroid disorders and hypocoagulability 1.186
The predictive ability of bleeding risk stratification models in very old patients on vitaminK antagonist treatment for venous thromboembolism: results of the prospective collaborative EPICA study 1.183
Clinical course of high-risk patients diagnosed with antiphospholipid syndrome 1.153
Aspetti immunologici nei tossicodipendenti anti-HIV sieronegativi. Correlazione con la durata di assunzione dell’eroina e con altre infezioni virali 1.139
High frequency of inadequate test requests for antiphospholipid antibodies in daily clinical practice 1.133
Vitamin K antagonists (coumarins), drugs used in the prevention and treatment of cardioembolism, deep vein thrombosis, and pulmonary embolism 1.129
Fetal programming of atherosclerosis: may the barker hypothesis explain the susceptibility of a subset of patients to develop stroke or cardiac infarct? 1.090
Vitamin K antagonist therapy: changes in the treated populations and in management results in Italian anticoagulation clinics compared with those recorded 20 years ago 1.086
A routine silica-based activated partial thromboplastin time (Hemosil aPTT-SP (TM)) mostly excludes the presence of lupus anticoagulant 1.078
Rheumatoid arthritis and thrombosis 1.078
Prevalence and significance of anti-prothrombin (aPT) antibodies in patients with Lupus Anticoagulant (LA) 1.072
Fetal programming of COVID-19: May the barker hypothesis explain the susceptibility of a subset of young adults to develop severe disease? 1.016
Plasma prekallikrein (Fletcher factor) in hepatic cirrhosis 1.014
Point-of-care (POCT) prothrombin time monitors: is a periodical control of their performance useful? 1.010
Infectious agents including COVID-19 and the involvement of blood coagulation and fibrinolysis. A narrative review 1.008
Clot characterization by multidisciplinary approach: biochemical and imaging parameters in a hypocoagulative setting. A pilot study 1.000
Hemarthrosis as acute presentation of acquired hemophilia in a patient with systemic lupus erythematosus: successful treatment and long-lasting remission 997
[Short-term effect of treatment with oral DL-carnitine and intravenous L-carnitine in chronic uremia patients undergoing hemodialytic therapy]. FT Effetto a breve termine della terapia con DL-carnitina per os ed L-carnitina e.v. nei pazienti uremici cronici in trattamento emodialitico. 983
Short-term effect of treatment with oral DL-carnitine and intravenous L-carnitine in chronic uremia patients undergoing hemodialytic therapy 948
Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results: a reply to a rebuttal 927
Center-related determinants of VKA anticoagulation quality: A prospective, multicenter evaluation 916
Thrombotic sinusoiditis and local diffuse intrasinusoidal coagulation in the liver of subjects affected by COVID-19: The evidence from histology and scanning electron microscopy 906
Aortic vulnerability to COVID-19: Is the microvasculature of vasa vasorum a key factor? A case report and a review of the literature 898
Scanning electron microscopy of lung disease due to COVID-19 – a case report and a review of the literature 843
Bleeding diathesis and gastro-duodenal ulcers in inherited cytosolic phospholipase-A2 alpha deficiency 836
Thromboembolic disease in patients with rheumatoid arthritis undergoing joint arthroplasty: Update on prophylaxes 833
Chronic intravascular coagulation in liver cirrhosis predicts a high hemorrhagic risk 832
Amoxicillina-acido clavulanico ed anticoagulanti orali:un’associazione potenzialmente pericolosa 830
Chronic spontaneous urticaria: a low-grade disseminated intravascular coagulation only partially reversed by Omalizumab 826
null 824
Start-register (Survey on anticoagulated patients register): the first year of activity 791
Clinical history and gastrointestinal bleeding in patients taking oral anticoagulants 780
null 772
Management of special conditions in patients on vitamin K antagonists 737
D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study 732
Bleeding risk in very old patients on vitamin K antagonist treatment: results of a prospective collaborative study on elderly patients followed by Italian Centres for Anticoagulation 692
null 679
Special indications for vitamin K antagonists: a review 676
Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study 674
null 644
Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results 636
Questions and answers on the use of dabigatran and perpectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA) 635
null 633
Response to imatinib in a patient with chronic myeloid leukemia simultaneously expressing p190(BCR-ABL) oncoprotein and JAK2(V617F) mutation 618
null 617
null 616
Totale 141.500
Salva come PNG Salva come JPEG
Categoria #
all - tutte 238.932
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 238.932
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.009 0 0 0 0 0 0 0 0 0 0 0 2.009
2021/20229.067 879 677 410 654 750 715 606 496 695 941 1.137 1.107
2022/202314.010 1.313 1.842 1.695 1.232 1.226 1.485 702 1.126 916 789 1.047 637
2023/202416.132 678 938 781 1.401 1.612 2.201 2.427 1.093 778 1.179 1.611 1.433
2024/202528.713 6.080 7.329 3.416 2.935 3.253 1.830 2.131 175 431 433 291 409
2025/202613.781 552 369 1.243 1.020 719 610 1.739 592 4.482 1.258 723 474
Totale 171.005